Uric acid as a predictor of endothelial dysfunction in patients with metabolic syndrome

Singh, Charanpreet; Jain, Sanjay; Dhawan, Veena; Kalra, Naveen; Kumari, Savita

doi:10.20945/2359-3997000000298

Cited by 9 publications

(8 citation statements)

References 21 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As endothelial dysfunction is also a primary pathogenic mechanism of ED, hyperuricaemia‐induced endothelial impairments might play a crucial role in ED seen in hyperuricaemia patients. Previous clinical studies have indeed demonstrated that uric acid was significantly associated with endothelial dysfunction in patients with metabolic syndrome (Singh et al, 2021), and that ED was an early manifestation of systemic vascular endothelial injury (Salem et al, 2009).…”

Section: Discussionmentioning

confidence: 95%

Hyperuricaemia is an important risk factor of the erectile dysfunction: A systematic review and meta‐analysis

et al. 2022

View full text Add to dashboard Cite

Serum uric acid can affect endothelial function, and hyperuricaemia‐induced endothelial dysfunction is involved in the pathogenesis of cardiovascular diseases. As endothelial dysfunction is also a main pathogenic mechanism of erectile dysfunction (ED), the present study aims to evaluate the relationship between hyperuricaemia and ED via systemic review and meta‐analysis. Five cohort studies and six cross‐sectional studies on hyperuricaemia and ED, including a total of 454,510 participants, were recruited. Odds ratio (OR) and the 95% confidence intervals (CI) were adopted to estimate the relationship between hyperuricaemia and ED. Overall risk on effects of urate‐lowering therapy (ULT) were analysed. In addition, subgroup analyses on study design, populations, age stratification and the object were conducted. In the patients with hyperuricaemia, the risk of ED was 1.59‐fold higher than (pooled OR = 1.59, 95% CI [1.29, 1.97]) the non‐hyperuricaemia counterparts. Urate‐lowing therapy (ULT) in these hyperuricaemia patients reduced the risk of ED by 27% (OR = 1.27, 95% CI [1.14, 1.41]). After subgroup analysis, the association between hyperuricaemia and ED remained significant apart from the >60 years subgroup. Hyperuricaemia is an important risk factor of ED, while ULT can reduce the risk of ED in hyperuricaemia. This study suggests that hyperuricaemia‐associated endothelial dysfunction may also underlie the pathogenesis of ED in these patients.

show abstract

Section: Discussionmentioning

confidence: 95%

Hyperuricaemia is an important risk factor of the erectile dysfunction: A systematic review and meta‐analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…As endothelial dysfunction is also a primary pathogenic mechanism of ED, hyperuricemia-induce endothelial impairments might play a crucial role in ED seen in hyperuricemia patients. Previous clinical studies have indeed demonstrated that uric acid was signi cantly associated with endothelial dysfunction in patients with metabolic syndrome [42], and that ED was an early manifestation of systemic vascular endothelial injury [43].…”

Section: Discussionmentioning

confidence: 95%

Hyperuricemia Is an Independent Risk Factor of the Erectile Dysfunction: a Systematic Review and Meta-analysis

Wang¹,

Jing²,

Liu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background and Aims: Serum uric acid can affect endothelial function, and hyperuricemia-induced endothelial dysfunction is involved in the pathogenesis of cardiovascular diseases. As endothelial dysfunction is also a main pathogenic mechanism of erectile dysfunction (ED), the present study aims to evaluate the relationship between hyperuricemia and ED via systemic review and meta-analysis.Methods: Five cohort studies and five cross-sectional studies on hyperuricemia and ED, including a total of 454256 participants, were recruited. Odds ratio (OR) and the 95% confidence intervals (CI) were adopted to estimate the relationship between hyperuricemia and ED. Overall risk were effects of urate-lowering therapy (ULT) analyzed. In addition, subgroup analyses on study design, populations, age stratification and the object were conducted.Results: In the patients with hyperuricemia, the risk of ED was 1.55-fold higher than (pooled OR=1.55, 95%CI (1.24,1.94)) the non-hyperuricemia counterparts. urate-lowing therapy (ULT) in these hyperuricemia patients reduced the risk of ED by 27% (OR=1.27, 95%CI (1.14,1.41)). After subgroup analysis and meta-regression, the association between hyperuricemia and ED remained significant apart from in the ≥55y subgroup.Conclusions: Hyperuricemia is an independent risk factor of ED, while ULT can reduce the risk of ED in hyperuricemia. This study suggests that hyperuricemia-associated endothelial dysfunction may also underlie the pathogenesis of ED in these patients.

show abstract

“…A cross-sectional study in patients with unilateral small kidney or renal agenesis conducted by Yazici et al demonstrated that the SUA level was positively correlated with arterial stiffness ( Yazici et al, 19932017 ). Mechanistic studies have shown that uric acid causes endothelial dysfunction, resulting in cardiovascular events ( Khosla et al, 2005 ; Liang et al, 2015 ; Lee et al, 2021 ; Singh et al, 2021 ). In our meta-analysis, we found that allopurinol might slightly reduce the risk of cardiovascular complications in only three RCTs.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Urate-Lowering Therapy for Renal Function in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials

Liang

Liu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background and Objective: Hyperuricemia is closely related to chronic kidney disease (CKD). The effects of urate-lowering therapy (ULT) on renal outcomes are uncertain, and whether it is warranted in CKD patients is currently unclear. The aim of our meta-analysis of randomized clinical trials (RCTs) was to assess the effectiveness and safety of ULT for improving kidney function in patients with CKD.Methods: RCTs were retrieved from the PubMed, Embase, MEDLINE and Cochrane Central Register of Controlled Trials databases. The meta-analysis was performed using Review Manager and Stata/SE software. The outcomes were changes in renal function and serum uric acid (SUA), serum creatinine, and adverse events.Results: Twelve RCTs with 1,469 participants were included in the meta-analysis. ULT was found to effectively lower SUA (standard mean difference (SMD): -2.70; 95% confidence interval (CI): -3.71, -1.69) but the renoprotective effects were not superior to those of control therapy (placebo or usual therapy), which were stable in the subgroup analyses and sensitivity analyses. Regarding adverse events, their risks did not increase in the ULT group compared with the control group and were stable in the sensitivity analyses.Conclusion: The findings of our meta-analysis suggested that ULT can effectively lower SUA, but there is insufficient evidence to support the renoprotective effects of ULT in CKD patients. In addition, ULT is safe for patients with CKD.Systematic Review Registration:https://clinicaltrials.gov/, identifier PROSPERO (CRD42020200550).

show abstract

Uric acid as a predictor of endothelial dysfunction in patients with metabolic syndrome

Cited by 9 publications

References 21 publications

Hyperuricaemia is an important risk factor of the erectile dysfunction: A systematic review and meta‐analysis

Hyperuricaemia is an important risk factor of the erectile dysfunction: A systematic review and meta‐analysis

Hyperuricemia Is an Independent Risk Factor of the Erectile Dysfunction: a Systematic Review and Meta-analysis

Effectiveness of Urate-Lowering Therapy for Renal Function in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials

Contact Info

Product

Resources

About